115 related articles for article (PubMed ID: 21514278)
1. The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein.
Vogler M; Dickens D; Dyer MJ; Owen A; Pirmohamed M; Cohen GM
Biochem Biophys Res Commun; 2011 May; 408(2):344-9. PubMed ID: 21514278
[TBL] [Abstract][Full Text] [Related]
2. Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood.
Vogler M; Furdas SD; Jung M; Kuwana T; Dyer MJ; Cohen GM
Clin Cancer Res; 2010 Aug; 16(16):4217-25. PubMed ID: 20601444
[TBL] [Abstract][Full Text] [Related]
3. Clinically relevant interactions of anti-apoptotic Bcl-2 protein inhibitors with ABC transporters.
Ruzickova E; Janska R; Dolezel P; Mlejnek P
Pharmazie; 2017 Dec; 72(12):751-758. PubMed ID: 29441961
[TBL] [Abstract][Full Text] [Related]
4. BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation.
Vogler M; Hamali HA; Sun XM; Bampton ET; Dinsdale D; Snowden RT; Dyer MJ; Goodall AH; Cohen GM
Blood; 2011 Jun; 117(26):7145-54. PubMed ID: 21562047
[TBL] [Abstract][Full Text] [Related]
5. Teaching an old drug new tricks: Actinomycin D synergistically enhances sensitivity to the Bcl-2 antagonist ABT-737.
Krystal GW
Cancer Biol Ther; 2010 Nov; 10(9):930-2. PubMed ID: 20935462
[No Abstract] [Full Text] [Related]
6. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
Yang H; Lee MH; Park I; Jeon H; Choi J; Seo S; Kim SW; Koh GY; Park KS; Lee DH
Cancer Lett; 2017 Dec; 411():19-26. PubMed ID: 28987383
[TBL] [Abstract][Full Text] [Related]
7. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
van Delft MF; Wei AH; Mason KD; Vandenberg CJ; Chen L; Czabotar PE; Willis SN; Scott CL; Day CL; Cory S; Adams JM; Roberts AW; Huang DC
Cancer Cell; 2006 Nov; 10(5):389-99. PubMed ID: 17097561
[TBL] [Abstract][Full Text] [Related]
8. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
Konopleva M; Milella M; Ruvolo P; Watts JC; Ricciardi MR; Korchin B; McQueen T; Bornmann W; Tsao T; Bergamo P; Mak DH; Chen W; McCubrey J; Tafuri A; Andreeff M
Leukemia; 2012 Apr; 26(4):778-87. PubMed ID: 22064351
[TBL] [Abstract][Full Text] [Related]
9. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
Mérino D; Khaw SL; Glaser SP; Anderson DJ; Belmont LD; Wong C; Yue P; Robati M; Phipson B; Fairlie WD; Lee EF; Campbell KJ; Vandenberg CJ; Cory S; Roberts AW; Ludlam MJ; Huang DC; Bouillet P
Blood; 2012 Jun; 119(24):5807-16. PubMed ID: 22538851
[TBL] [Abstract][Full Text] [Related]
10. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.
Vogler M; Butterworth M; Majid A; Walewska RJ; Sun XM; Dyer MJ; Cohen GM
Blood; 2009 Apr; 113(18):4403-13. PubMed ID: 19008458
[TBL] [Abstract][Full Text] [Related]
11. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
12. Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells.
Huang S; Sinicrope FA
Autophagy; 2010 Feb; 6(2):256-69. PubMed ID: 20104024
[TBL] [Abstract][Full Text] [Related]
13. Different forms of cell death induced by putative BCL2 inhibitors.
Vogler M; Weber K; Dinsdale D; Schmitz I; Schulze-Osthoff K; Dyer MJ; Cohen GM
Cell Death Differ; 2009 Jul; 16(7):1030-9. PubMed ID: 19390557
[TBL] [Abstract][Full Text] [Related]
14. Mcl-1 levels need not be lowered for cells to be sensitized for ABT-263/737-induced apoptosis.
Yamaguchi R; Perkins G
Cell Death Dis; 2011 Nov; 2(11):e227. PubMed ID: 22071632
[No Abstract] [Full Text] [Related]
15. Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy.
Yamaguchi R; Janssen E; Perkins G; Ellisman M; Kitada S; Reed JC
PLoS One; 2011; 6(9):e24102. PubMed ID: 21949692
[TBL] [Abstract][Full Text] [Related]
16. Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition.
Tamaki H; Harashima N; Hiraki M; Arichi N; Nishimura N; Shiina H; Naora K; Harada M
Oncotarget; 2014 Nov; 5(22):11399-412. PubMed ID: 25333266
[TBL] [Abstract][Full Text] [Related]
17. Functional inhibition of BCL2 is needed to increase the susceptibility to apoptosis to SMO inhibitors in diffuse large B-cell lymphoma of germinal center subtype.
Kunkalla K; Liu Y; Qu C; Leventaki V; Agarwal NK; Singh RR; Vega F
Ann Hematol; 2013 Jun; 92(6):777-87. PubMed ID: 23370596
[TBL] [Abstract][Full Text] [Related]
18. Rapid detection of an ABT-737-sensitive primed for death state in cells using microplate-based respirometry.
Clerc P; Carey GB; Mehrabian Z; Wei M; Hwang H; Girnun GD; Chen H; Martin SS; Polster BM
PLoS One; 2012; 7(8):e42487. PubMed ID: 22880001
[TBL] [Abstract][Full Text] [Related]
19. Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy.
Karlsson H; Lindqvist AC; Fransson M; Paul-Wetterberg G; Nilsson B; Essand M; Nilsson K; Frisk P; Jernberg-Wiklund H; Loskog A
Cancer Gene Ther; 2013 Jul; 20(7):386-93. PubMed ID: 23788110
[TBL] [Abstract][Full Text] [Related]
20. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.
Séveno C; Loussouarn D; Bréchet S; Campone M; Juin P; Barillé-Nion S
Breast Cancer Res; 2012 Jun; 14(3):R96. PubMed ID: 22703841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
